Corvus Historical Income Statement

CRVS Stock

USD 8.93 0.02 0.22%

Historical analysis of Corvus Pharmaceuticals income statement accounts such as Interest Expense of 864.5 K, Selling General Administrative of 8.6 M or Total Revenue of 0.0 can show how well Corvus Pharmaceuticals performed in making a profits. Evaluating Corvus Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Corvus Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Corvus Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Corvus Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corvus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Corvus Stock please use our How to Invest in Corvus Pharmaceuticals guide.

About Corvus Income Statement Analysis

Corvus Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Corvus Pharmaceuticals shareholders. The income statement also shows Corvus investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Corvus Pharmaceuticals Income Statement Chart

At this time, Corvus Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Other Operating Expenses is likely to gain to about 37.8 M in 2024, whereas Interest Expense is likely to drop slightly above 864.5 K in 2024.

Selling General Administrative Gross Profit Other Operating Expenses Research Development Total Operating Expenses Reconciled Depreciation

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Corvus Pharmaceuticals minus its cost of goods sold. It is profit before Corvus Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Corvus Pharmaceuticals. It is also known as Corvus Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Corvus Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Corvus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corvus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Corvus Stock please use our How to Invest in Corvus Pharmaceuticals guide.At this time, Corvus Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Other Operating Expenses is likely to gain to about 37.8 M in 2024, whereas Interest Expense is likely to drop slightly above 864.5 K in 2024.

Corvus Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Selling General Administrative	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Interest Income	Ebitda	Net Interest Income	Non Operating Income Net Other	Reconciled Depreciation	Selling And Marketing Expenses
Depreciation And Amortization		0.78	-0.98	0.84	-0.89	-0.65	-0.85	0.85	0.98	0.84	-0.67	0.39	-0.64	-0.35	-0.62	-0.9	0.46	-0.12	0.21	0.34
Selling General Administrative	0.78		-0.88	0.98	-0.96	-0.77	-0.97	0.96	0.87	0.98	-0.77	0.35	-0.74	0.08	-0.94	-0.94	0.39	0.5	-0.42	-0.18
Gross Profit	-0.98	-0.88		-0.93	0.96	0.76	0.93	-0.93	-1.0	-0.93	0.78	-0.33	0.75	0.23	0.74	0.95	-0.46	-0.04	-0.05	-0.2
Other Operating Expenses	0.84	0.98	-0.93		-0.99	-0.85	-0.98	1.0	0.92	1.0	-0.84	0.26	-0.82	0.03	-0.9	-0.96	0.41	0.34	-0.29	-0.14
Operating Income	-0.89	-0.96	0.96	-0.99		0.84	0.99	-0.99	-0.96	-0.99	0.85	-0.28	0.82	0.06	0.87	0.98	-0.42	-0.27	0.21	-0.01
Net Income From Continuing Ops	-0.65	-0.77	0.76	-0.85	0.84		0.86	-0.86	-0.76	-0.85	1.0	0.28	0.99	-0.11	0.76	0.81	-0.42	-0.22	0.29	0.12
Ebit	-0.85	-0.97	0.93	-0.98	0.99	0.86		-0.98	-0.93	-0.98	0.86	-0.23	0.85	-0.01	0.91	0.98	-0.39	-0.36	0.3	0.03
Research Development	0.85	0.96	-0.93	1.0	-0.99	-0.86	-0.98		0.93	1.0	-0.86	0.23	-0.84	0.01	-0.88	-0.96	0.42	0.3	-0.25	-0.12
Cost Of Revenue	0.98	0.87	-1.0	0.92	-0.96	-0.76	-0.93	0.93		0.92	-0.78	0.33	-0.75	-0.23	-0.74	-0.95	0.46	0.04	0.05	0.21
Total Operating Expenses	0.84	0.98	-0.93	1.0	-0.99	-0.85	-0.98	1.0	0.92		-0.84	0.26	-0.82	0.03	-0.9	-0.96	0.41	0.34	-0.29	-0.14
Income Before Tax	-0.67	-0.77	0.78	-0.84	0.85	1.0	0.86	-0.86	-0.78	-0.84		0.28	0.99	-0.07	0.74	0.81	-0.41	-0.18	0.25	0.07
Total Other Income Expense Net	0.39	0.35	-0.33	0.26	-0.28	0.28	-0.23	0.23	0.33	0.26	0.28		0.31	-0.24	-0.23	-0.3	0.02	0.17	0.08	0.13
Net Income	-0.64	-0.74	0.75	-0.82	0.82	0.99	0.85	-0.84	-0.75	-0.82	0.99	0.31		-0.15	0.74	0.8	-0.4	-0.2	0.27	0.07
Income Tax Expense	-0.35	0.08	0.23	0.03	0.06	-0.11	-0.01	0.01	-0.23	0.03	-0.07	-0.24	-0.15		-0.29	0.07	0.22	0.57	-0.71	-0.74
Interest Income	-0.62	-0.94	0.74	-0.9	0.87	0.76	0.91	-0.88	-0.74	-0.9	0.74	-0.23	0.74	-0.29		0.87	-0.3	-0.64	0.61	0.33
Ebitda	-0.9	-0.94	0.95	-0.96	0.98	0.81	0.98	-0.96	-0.95	-0.96	0.81	-0.3	0.8	0.07	0.87		-0.39	-0.28	0.21	-0.06
Net Interest Income	0.46	0.39	-0.46	0.41	-0.42	-0.42	-0.39	0.42	0.46	0.41	-0.41	0.02	-0.4	0.22	-0.3	-0.39		-0.13	0.0	-0.13
Non Operating Income Net Other	-0.12	0.5	-0.04	0.34	-0.27	-0.22	-0.36	0.3	0.04	0.34	-0.18	0.17	-0.2	0.57	-0.64	-0.28	-0.13		-0.94	-0.61
Reconciled Depreciation	0.21	-0.42	-0.05	-0.29	0.21	0.29	0.3	-0.25	0.05	-0.29	0.25	0.08	0.27	-0.71	0.61	0.21	0.0	-0.94		0.74
Selling And Marketing Expenses	0.34	-0.18	-0.2	-0.14	-0.01	0.12	0.03	-0.12	0.21	-0.14	0.07	0.13	0.07	-0.74	0.33	-0.06	-0.13	-0.61	0.74

Click cells to compare fundamentals

Corvus Pharmaceuticals Account Relationship Matchups

Corvus Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	743K	632K	460K	367K	151K	143.5K
Interest Expense	2.2M	540K	15K	654K	1.6M	864.5K
Selling General Administrative	10.9M	11.9M	9.5M	8.1M	6.9M	8.6M
Gross Profit	(743K)	(632K)	(460K)	(367K)	(151K)	(158.6K)
Other Operating Expenses	48.9M	43.8M	38.6M	32.6M	23.4M	37.8M
Operating Income	(48.9M)	(43.8M)	(38.6M)	(32.6M)	(23.3M)	(24.5M)
Net Income From Continuing Ops	(46.7M)	(6.0M)	(43.2M)	(41.3M)	(30.2M)	(31.7M)
Ebit	(48.9M)	(43.8M)	(43.2M)	(41.3M)	(27.0M)	(28.4M)
Research Development	38.0M	31.8M	29.1M	24.5M	16.5M	29.2M
Cost Of Revenue	743K	632K	460K	367K	151K	143.5K
Total Operating Expenses	48.9M	43.8M	38.6M	32.6M	23.4M	37.8M
Income Before Tax	(46.7M)	(6.0M)	(43.2M)	(41.3M)	(27.0M)	(28.4M)
Total Other Income Expense Net	2.2M	37.8M	(4.6M)	(8.7M)	(3.7M)	(3.5M)
Net Income Applicable To Common Shares	(46.7M)	(6.0M)	(43.2M)	(41.3M)	(37.2M)	(39.0M)
Net Income	(43.7M)	(4.8M)	(38.2M)	(50.0M)	(27.0M)	(28.4M)
Income Tax Expense	(2.9M)	(1.2M)	(5.0M)	8.7M	10.1M	10.6M
Interest Income	2.3M	2.2M	540K	6K	5.4K	5.1K
Ebitda	(48.1M)	(43.1M)	(42.8M)	(40.9M)	(26.9M)	(28.2M)
Net Interest Income	2.2M	540K	(15K)	654K	1.5M	862.8K
Reconciled Depreciation	743K	632K	460K	367K	217K	206.2K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Corvus Stock Analysis

When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Corvus Historical Income Statement

About Corvus Income Statement Analysis

Corvus Pharmaceuticals Income Statement Chart

Gross Profit

Other Operating Expenses

Total Operating Expenses

Corvus Pharmaceuticals income statement Correlations

Corvus Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Corvus Pharmaceuticals income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Corvus Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Income Before Tax	+ 1.0	Net Income From Continuing Ops
Total Operating Expenses	+ 1.0	Research Development
Ebit	+ 0.99	Operating Income
Net Income	+ 0.99	Net Income From Continuing Ops

Cost Of Revenue	- 1.0	Gross Profit
Total Operating Expenses	- 0.99	Operating Income
Research Development	- 0.99	Operating Income
Operating Income	- 0.99	Other Operating Expenses
Total Operating Expenses	- 0.98	Ebit
Research Development	- 0.98	Ebit